AU2019293235B2 - Immunomodulatory compounds - Google Patents

Immunomodulatory compounds Download PDF

Info

Publication number
AU2019293235B2
AU2019293235B2 AU2019293235A AU2019293235A AU2019293235B2 AU 2019293235 B2 AU2019293235 B2 AU 2019293235B2 AU 2019293235 A AU2019293235 A AU 2019293235A AU 2019293235 A AU2019293235 A AU 2019293235A AU 2019293235 B2 AU2019293235 B2 AU 2019293235B2
Authority
AU
Australia
Prior art keywords
optionally
membered
group
substituted
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019293235A
Other languages
English (en)
Other versions
AU2019293235A1 (en
Inventor
Katherine DONOVAN
Guangyan DU
Eric Fischer
Nathanael Gray
Zhixiang HE
Hu Liu
Radoslaw Nowak
Alyssa VERANO
Jing Ting Christine YUAN
Tinghu Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2019293235A1 publication Critical patent/AU2019293235A1/en
Application granted granted Critical
Publication of AU2019293235B2 publication Critical patent/AU2019293235B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2019293235A 2018-06-29 2019-06-27 Immunomodulatory compounds Active AU2019293235B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862692176P 2018-06-29 2018-06-29
US62/692,176 2018-06-29
PCT/US2019/039509 WO2020006233A1 (en) 2018-06-29 2019-06-27 Immunomodulatory compounds

Publications (2)

Publication Number Publication Date
AU2019293235A1 AU2019293235A1 (en) 2020-12-17
AU2019293235B2 true AU2019293235B2 (en) 2025-07-03

Family

ID=68987232

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019293235A Active AU2019293235B2 (en) 2018-06-29 2019-06-27 Immunomodulatory compounds

Country Status (8)

Country Link
US (1) US12234220B2 (enExample)
EP (1) EP3814330A4 (enExample)
JP (2) JP7328263B2 (enExample)
KR (1) KR102834593B1 (enExample)
CN (1) CN113166100A (enExample)
AU (1) AU2019293235B2 (enExample)
CA (1) CA3102212A1 (enExample)
WO (1) WO2020006233A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3679026A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Glutarimide
CN113166100A (zh) * 2018-06-29 2021-07-23 达纳-法伯癌症研究所有限公司 免疫调节性化合物
KR20210152515A (ko) 2019-04-12 2021-12-15 씨4 테라퓨틱스, 인코포레이티드 이카로스 및 아이올로스의 트리시클릭 분해제
AU2020392427B2 (en) * 2019-11-27 2024-03-07 Captor Therapeutics S.A. Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof
IL293530A (en) 2019-12-18 2022-08-01 Novartis Ag Derivatives of 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione and their uses
WO2022255889A1 (en) * 2021-06-01 2022-12-08 Captor Therapeutics S.A. Compounds which bind to cereblon, and use thereof
AR126052A1 (es) 2021-06-03 2023-09-06 Novartis Ag Derivados de 3-(5-oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos
IL319458A (en) 2022-09-09 2025-05-01 Innovo Therapeutics Inc Compounds that reduce ck1α and dual ck1α/gspt1
CN116655595A (zh) * 2023-06-05 2023-08-29 中国人民解放军军事科学院军事医学研究院 2,6-哌啶二酮衍生物及其制备和用途
WO2025063888A1 (en) 2023-09-19 2025-03-27 Kancure Pte. Ltd. Survivin-targeted compounds
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017161119A1 (en) * 2016-03-16 2017-09-21 H. Lee Moffitt Cancer Center & Research Institute, Inc. Small molecules against cereblon to enhance effector t cell function
WO2017197051A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
WO2008007979A1 (en) * 2006-07-12 2008-01-17 Auckland Uniservices Limited (2,6-dioxo-3-piperinyl)amidobenzoic immunomodulatory and anti-cancer derivatives
EP3577109A4 (en) 2017-01-31 2020-11-18 Arvinas Operations, Inc. CEREMONY LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM
EP3679026A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Glutarimide
EP3737675A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
CN113166100A (zh) * 2018-06-29 2021-07-23 达纳-法伯癌症研究所有限公司 免疫调节性化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017161119A1 (en) * 2016-03-16 2017-09-21 H. Lee Moffitt Cancer Center & Research Institute, Inc. Small molecules against cereblon to enhance effector t cell function
WO2017197051A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation

Also Published As

Publication number Publication date
US20210284624A1 (en) 2021-09-16
JP7328263B2 (ja) 2023-08-16
KR20210027395A (ko) 2021-03-10
JP2023145694A (ja) 2023-10-11
KR102834593B1 (ko) 2025-07-16
AU2019293235A1 (en) 2020-12-17
CN113166100A (zh) 2021-07-23
US12234220B2 (en) 2025-02-25
WO2020006233A1 (en) 2020-01-02
CA3102212A1 (en) 2020-01-02
JP2021530453A (ja) 2021-11-11
EP3814330A4 (en) 2022-07-20
EP3814330A1 (en) 2021-05-05

Similar Documents

Publication Publication Date Title
AU2019293235B2 (en) Immunomodulatory compounds
AU2019294835B2 (en) Ligands to cereblon (CRBN)
AU2019371400B2 (en) Acetylation writer inhibitor development and uses thereof
AU2019261938B2 (en) Small molecule degraders of polybromo-1 (PBRM1)
AU2019220632B2 (en) IRAK degraders and uses thereof
US20230002397A1 (en) Small molecule degraders of helios and metods of use
AU2019294836B2 (en) Bispecific degraders
EP4110340A1 (en) Potent and selective degraders of alk
US20240376096A1 (en) Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof
AU2020295399B2 (en) Small molecule target bromo/acetyl proteins and uses thereof
CA3172589A1 (en) Piperidine-2,6-diones as small molecule degraders of helios and methods of use
CA3132348A1 (en) Degraders of fibroblast growth factor receptor 2 (fgfr2)
AU2019346595B2 (en) Macrocyclic inhibitors of ALK, TRKA, TRKB, TRKC and ROS1

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ GRAY, NATHANAEL; ZHANG, TINGHU; FISCHER, ERIC; VERANO, ALYSSA; HE, ZHIXIANG; DU, GUANGYAN; DONOVAN, KATHERINE; NOWAK, RADOSLAW; YUAN, JING TING CHRISTINE AND LIU, HU

FGA Letters patent sealed or granted (standard patent)